Mastermind in Life Sciences Advocacy and Access, Championing Rare Disease Solutions
With a remarkable 25-year Life Sciences tenure, Michael Eging is a distinguished professional in Global, State, and Federal Government Affairs, Advocacy, Communications, and Market Access. Specializing in reimbursement solutions across Medicare, Medicaid, and ADAP, he has also demonstrated expertise in the commercial market access space.
Michael’s notable achievements include launching the Rare Access Action Project, a 501(c)(4) coalition uniting rare disease companies and patient organizations to forge access solutions. As a seasoned Public and Government Affairs executive, he has orchestrated comprehensive initiatives across various therapeutic areas, achieving significant successes in appropriations, authorizations, and patient access to support emerging companies in the rare disease sector.
With a quarter-century of experience in industry advocacy coalitions and trade organizations, Michael has been an active participant and leader in groups such as the ADAP Working Group, BIO, PhRMA, HINJ, and Mass BIO. His involvement extends to the Boards of Pharmacy, focusing on pain management and other therapeutic issues.
Michael has dedicated 15 years to cultivating robust relationships across patient and policy communities in rare diseases, including collaborations with NORD, Global Genes, Everylife, RDLA, and various therapeutic-focused organizations. His long-time tenure further exemplifies his commitment to community service as a board member for the Title II Community AIDS National Network (TIICANN) and the Community Access National Network.
Michael also contributed as a writer and editor for critical publications like the Medicaid Pharmacy Bulletin, the ADAP Report, and State Policy Point. Passionate about advocating for patients who often go unheard, he is driven by a mission to develop solutions that genuinely impact patient lives, embodying the spirit of a true advocate in the life sciences field.
Get in touch: